Evidence map›Paper›PMID 38751641›Full record

ArticleACS pharmacology & translational science2024

Insights into Mechanisms and Promising Triple Negative Breast Cancer Therapeutic Potential for a Water-Soluble Ruthenium Compound.

Nazia Nayeem, Sami Sauma, Afruja Ahad, Rachele Rameau, Sophia Kebadze, Mark Bazett, Brian J Park, Patrizia Casaccia, Swayam Prabha, Karen Hubbard and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS pharmacology & translational science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Therapeutic Potential of Metal-Based and PARP Inhibitor Chemotherapy forInternational journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Nazia NayeemDepartment of Chemistry, Brooklyn College, The City University of New York, Brooklyn, New York 11210, United States.
Sami SaumaBiology PhD Program The Graduate Center, The City University of New York, New York, New York 10016, United States.
Afruja AhadDepartment of Chemistry, Brooklyn College, The City University of New York, Brooklyn, New York 11210, United States.ORCID https://orcid.org/0009-0007-3887-9363
Rachele RameauBiology PhD Program The Graduate Center, The City University of New York, New York, New York 10016, United States.
Sophia KebadzeDepartment of Chemistry, Brooklyn College, The City University of New York, Brooklyn, New York 11210, United States.
Mark BazettBold Therapeutics Inc., Vancouver, British Columbia V6C 1E1, Canada.
Brian J ParkBold Therapeutics Inc., Vancouver, British Columbia V6C 1E1, Canada.
Patrizia CasacciaNeuroscience Initiative, Advanced Science Research Center, New York, New York 10065, United States.
Swayam PrabhaFels Cancer Institute for Personalized Medicine and Department of Cancer and Cellular Biology, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania 19104, United States.ORCID https://orcid.org/0000-0001-6475-5494
Karen HubbardBiology PhD Program The Graduate Center, The City University of New York, New York, New York 10016, United States.
Maria ContelDepartment of Chemistry, Brooklyn College, The City University of New York, Brooklyn, New York 11210, United States.ORCID https://orcid.org/0000-0002-9825-4441

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Training and Career Development CoreU54CA132378 · NCI · CITY COLLEGE OF NEW YORK · PI Tim Alan Ahles, ADRIANA ESPINOSA · 2008 to 2026
$28.9M
Training and Career Development and Education CoreU54CA137788 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Daniel Alan Heller · 2008 to 2026
$28.1M
Research Center in Minority Institutions (RCMI) at City CollegeU54MD017979 · NIMHD · CITY COLLEGE OF NEW YORK · PI M. Felice Marina GHILARDI · 2024 to 2026
$15.9M
Environmental Biosensors in the Oligodendrocyte LineageR35NS111604 · NINDS · ADVANCED SCIENCE RESEARCH CENTER · PI Patrizia Casaccia · 2019 to 2026
$9.1M
G-RISE: Graduate Research Initiative for Student Advancement at The City College of New YorkT32GM136499 · NIGMS · CITY COLLEGE OF NEW YORK · PI RUTH E. STARK · 2020 to 2026
$4.9M
Biodegradable nanocarriers and antibodies as targeting delivery vehicles for cancer metallodrugsSC1GM127278 · NIGMS · BROOKLYN COLLEGE · PI CONTEL, MARIA · 2018 to 2021
$1.6M
Platinum-Gold Compounds as Potential Chemo- and Targeted Agents for Ovarian CancerR16GM149396 · NIGMS · BROOKLYN COLLEGE · PI Maria Contel · 2023 to 2026
$643k
NCI NIH HHS P30 CA008748NCI NIH HHS U54 CA132378NCI NIH HHS U54 CA137788NIGMS NIH HHS R16 GM149396NIGMS NIH HHS SC1 GM127278NIGMS NIH HHS T32 GM136499NIMHD NIH HHS U54 MD017979NINDS NIH HHS R35 NS111604
6 · The paper itself

Abstract

Triple negative breast cancer (TNBC) represents a subtype of breast cancer that does not express the three major prognostic receptors of human epidermal growth factor receptor 2 (HER2), progesterone (PR), and estrogen (ER). This limits treatment options and results in a high rate of mortality. We have reported previously on the efficacy of a water-soluble, cationic organometallic compound (

Identifiers

PMID38751641
PMCPMC11092013

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.